Inogen Inc expected to post a loss of 36 cents a share - Earnings Preview
Inogen Inc (INGN) is projected to report a loss of 36 cents per share, according to a recent earnings preview. This forecast is based on information from Refinitiv. The article provides a brief earnings outlook for the company.
Inogen (INGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Inogen (INGN) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results due on February 24. Despite a consensus outlook predicting a quarterly loss of $0.36 per share, slightly better than the previous year, the estimate has been revised 5.26% lower recently. With an Earnings ESP of 0% and a Zacks Rank #2, it's difficult to conclusively predict whether Inogen will beat or miss the consensus EPS estimate.
Inogen (INGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Inogen (INGN) is expected to report a quarterly loss of $0.36 per share, an improvement from the previous year, with revenues projected to increase by 2.4% to $82 million for the quarter ended December 2025. Despite a Zacks Rank #2 (Buy), the company has an Earnings ESP of 0%, making it difficult to confidently predict an earnings beat. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank when evaluating the stock.
Inogen (INGN) to Release Quarterly Earnings on Tuesday
Inogen (NASDAQ:INGN) is set to release its Q4 2025 earnings after the market closes on Tuesday, February 24, 2026. Analysts project an EPS loss of ($0.36) and revenue of $82.0 million for the quarter. The medical technology company, with a market capitalization of $156.38 million, has seen institutional investors acquire significant stakes, while analyst ratings are mixed with an average "Hold" rating and a consensus target price of $11.00.
Inogen (INGN) Soars 6.6%: Is Further Upside Left in the Stock?
Inogen (INGN) shares rose 6.6% after the company provided an encouraging preliminary revenue update for Q4 2025, showing modest top-line growth and expected positive adjusted EBITDA for the full year. While expected revenues are up 2.4% year over year, the consensus EPS estimate for the upcoming quarter has been revised 5.3% lower, suggesting potential headwinds despite the recent stock jump. Inogen currently holds a Zacks Rank #2 (Buy).
Inogen (INGN) Loses 10.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inogen (INGN) has seen a 10% decline in stock value over the past four weeks, reaching an oversold position according to its Relative Strength Index (RSI) of 29.69. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zacks Rank #2 (Buy), suggests a potential trend reversal and rebound for the stock. Investors may find this an opportune time to consider entry.
Inogen (NASDAQ:INGN) Stock Crosses Below 200 Day Moving Average - Time to Sell?
Inogen (NASDAQ:INGN) stock recently dipped below its 200-day moving average, trading at $5.84, signaling technical weakness. Despite negative earnings and margins, institutional ownership remains high at nearly 90%, with firms like AQR and Goldman Sachs increasing their stakes. Analysts are divided, with a "Sell" rating from Weiss Ratings and a "Hold" consensus from MarketBeat, with an average target price of $11.00.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Inogen (INGN) is positioned for growth due to strong prospects in the portable oxygen concentrator (POC) market, solid third-quarter 2025 performance, and an expanding product portfolio. Although facing competition and forex volatility, the company projects significant earnings growth for 2026 and has an attractive valuation. The expansion of its product lineup and strategic partnerships are also key growth drivers.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) reported a narrower-than-expected Q1 loss of $0.25 per share, surpassing the Zacks Consensus Estimate of a $0.52 loss, and also exceeded revenue expectations with $82.28 million. Despite underperforming the market year-to-date, the company has consistently beaten EPS and revenue estimates over the last four quarters. The article also discusses Inogen's Zacks Rank #3 (Hold) and provides an outlook for its future performance and that of a peer company, 908 Devices Inc. (MASS).
Inogen (NASDAQ:INGN shareholders incur further losses as stock declines 11% this week, taking five-year losses to 86%
Inogen (NASDAQ:INGN) shareholders have experienced significant losses, with the stock declining 11% this week and an overall 86% loss over the past five years. The company's revenue growth has been modest at 0.4% annually over five years, and it is currently unprofitable, leading to market disappointment. Despite insider purchases, the stock's long-term underperformance suggests a need for the company to demonstrate profitability to attract new investors.
Inogen (NASDAQ:INGN shareholders incur further losses as stock declines 11% this week, taking five-year losses to 86%
Inogen (NASDAQ:INGN) shareholders have experienced significant losses, with the stock declining 11% this week and an overall 86% loss over the past five years. Despite the ongoing losses and a 40% decline in the last year, revenue growth has been minimal at 0.4% annually, while the company remains unprofitable. Insiders have made purchases, but analysts' future profit estimates will be crucial for potential investors.
Inogen (NASDAQ:INGN shareholders incur further losses as stock declines 11% this week, taking five-year losses to 86%
Inogen (NASDAQ:INGN) shareholders have experienced significant losses, with an 11% decline this week and an 86% drop over the past five years. The company's revenue growth has been minimal at 0.4% per year over five years, and it currently operates at a loss, leading to market disappointment. Despite insider purchases, the stock's poor performance suggests a need for the company to achieve profitability to regain investor confidence.
Respiratory device maker Inogen edges toward profitability in 2025
Inogen announced preliminary unaudited revenue results for Q4 and full-year 2025, expecting approximately $82 million and $349 million respectively, showing year-over-year growth. The company anticipates achieving positive Adjusted EBITDA for the full year 2025, reflecting progress in its turnaround strategy despite some Q4 customer order timing shifts. Inogen also highlighted pipeline expansion with new product launches and expressed confidence in accelerating growth and profitability into 2026.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen announced preliminary, unaudited revenue results for Q4 and full-year 2025, with an estimated total revenue of $82 million for Q4 (2% year-over-year growth) and $349 million for the full year (4% growth). The company anticipates achieving positive Adjusted EBITDA for 2025, reflecting financial discipline and effective cost management. Inogen will host a conference call on February 24, 2026, to discuss financial results and provide 2026 financial guidance, noting a shift in some large customer orders to early 2026.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen, Inc. announced preliminary, unaudited revenue results for Q4 and the full year 2025. The company anticipates approximately $92 million in revenue for Q4 2025, representing a 2% year-over-year growth, and approximately $376 million for the full year 2025, showing 6% year-over-year growth. Despite strong performance in business-to-business channels, a shift in large customer orders impacted Q4 results, though full-year progress was made on their business turnaround, including positive Adjusted EBITDA and new product launches.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen announced preliminary, unaudited revenue results for Q4 and full-year 2025, expecting approximately $82 million for the quarter (2% year-over-year growth) and $349 million for the full year (4% year-over-year growth). The company anticipates achieving positive Adjusted EBITDA for the full year 2025 and will share additional details and 2026 financial guidance during its earnings call on February 24, 2026. Despite a delay in some large customer orders, Inogen highlights positive revenue growth, progress towards profitability, and innovation pipeline expansion with new product launches.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen, Inc. announced preliminary unaudited revenue results for the fourth quarter and full-year 2025. The company expects approximately $82 million in revenue for Q4 2025, representing 2% year-over-year growth, and $349 million for the full year, a 4% increase. Despite a slight delay in some customer orders, Inogen remains confident in achieving positive Adjusted EBITDA for the full year and looks forward to sharing more details and 2026 guidance during its February 24, 2026 earnings call.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full-year 2025. The company expects approximately $82 million in revenue for Q4 2025, a 2% year-over-year increase, and approximately $349 million for the full year 2025, representing a 4% year-over-year growth. Inogen also anticipates achieving positive Adjusted EBITDA for the full year 2025 and will share additional details and 2026 financial guidance on February 24, 2026.
Inogen adds ‘innovation’ to CPAP market
Inogen has launched its new Aurora line of CPAP masks, marking its entry into the CPAP market in partnership with Yuwell. This move positions Inogen as a broader respiratory solutions company, complementing its existing oxygen concentrator business. The company emphasizes clinical validation and patient preference for its new mask line, with plans to potentially introduce CPAP devices in the future.
New Line of CPAP Masks Launches
Inogen has expanded into the sleep therapy market by launching its Aurora CPAP masks in the United States. This new product line for obstructive sleep apnea patients includes full face, nasal cushion, and nasal pillow masks. The company aims to leverage its existing distribution channels and has reported high patient satisfaction from a 30-day study.
Inogen Launches Aurora CPAP Masks for Sleep Apnea
Inogen Inc., a leader in portable oxygen therapeutics, has officially launched its Aurora CPAP mask brand, marking its entry into the sleep apnea market. This strategic move expands Inogen's focus to become a broader provider of home respiratory care solutions. The Aurora masks are designed for comfort, ease of use, and durability, and have received FDA 510(k) clearance, reflecting Inogen's commitment to quality and safety in the rapidly evolving sleep therapy market.
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
Inogen, Inc. (INGN) shares rose nearly 7.8% following the launch of its new Aurora CPAP (continuous positive airway pressure) masks for Obstructive Sleep Apnea (OSA) in the United States. This FDA 510(k)-cleared product line aims to expand Inogen's respiratory care portfolio and strengthen its position in the growing sleep-therapy market. The global sleep apnea devices market is projected to reach $6.9 billion by 2030, driven by technological advancements and an aging population, providing a significant growth opportunity for Inogen.
Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States
Inogen, Inc. (Nasdaq: INGN) has introduced Aurora CPAP masks to the U.S. market, expanding its respiratory product portfolio to include solutions for obstructive sleep apnea. This strategic move aims to leverage Inogen's existing distribution channels and bolster its presence in the growing sleep-therapy market. The Aurora line, including full face, nasal cushion, and nasal pillows options, was developed for comfort, reliability, and usability, supported by a patient-use study.
Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States
Inogen, Inc. has announced the launch of its new Aurora CPAP masks for obstructive sleep apnea (OSA) in the United States, expanding its respiratory care portfolio. This move signifies Inogen's entry into the sleep apnea market, complementing their existing respiratory solutions. The Aurora masks are designed for comfort, reliability, and usability, aiming to cater to diverse patient needs and promote consistent therapy adherence.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market
Inogen has launched its new Aurora CPAP masks, marking its entry into the sleep apnea market to address the needs of patients with obstructive sleep apnea. These masks are designed for superior comfort and reliability, with a patient-use study showing high satisfaction rates among participants. The company plans to leverage its existing distribution channels and partnerships to bring the Aurora masks to market, aiming to enhance its competitiveness and leadership in home respiratory care.
Inogen launches Aurora CPAP masks, enters sleep apnea market
Inogen Inc. has expanded into the sleep apnea market with the launch of its new Aurora CPAP masks, moving beyond its traditional oxygen therapy focus. These FDA 510(k) cleared masks are designed for comfort, reliability, and universal compatibility, aiming to improve patient adherence to CPAP therapy. The launch leverages Inogen's existing distribution channels and aligns with broader trends in sleep therapy towards enhanced comfort, digital integration, and AI-driven adjustments to improve patient outcomes.
Inogen launches Aurora CPAP masks, expanding into sleep apnea market By Investing.com
Inogen, Inc. (NASDAQ:INGN) has launched its new Aurora CPAP masks, marking its entry into the sleep apnea market with three models: F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows. These FDA 510(k) cleared masks are compatible with most CPAP devices and feature a triple-material headgear and honeycomb vent design. This expansion aligns with Inogen's strategy to broaden its respiratory care portfolio, following strong patient satisfaction in August 2025 studies and recent Q3 2025 earnings which beat EPS forecasts.
New CPAP masks offer quieter nights for people with sleep apnea
Inogen, Inc. (Nasdaq: INGN) has launched its new Aurora CPAP masks for obstructive sleep apnea in the United States, expanding its respiratory care portfolio. These masks are designed for superior comfort, reliability, and usability, targeting the growing sleep-therapy market. The Aurora line includes full face, nasal cushion, and nasal pillows options, all FDA 510(k) Cleared and supported by a patient-use study showing high satisfaction.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Inogen, Inc. (INGN) is identified as a strong buy due to high prospects in the portable oxygen concentrator (POC) market, solid third-quarter 2025 performance, and an expanding product portfolio. Despite challenges like competition and forex volatility, the company's valuation is attractive, and it projects significant earnings growth for 2026. The article highlights key factors driving INGN's potential, such as market growth in POCs, strategic collaborations, and expanding product lines.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Inogen, Inc. (INGN) is projected for significant growth in the portable oxygen concentrator (POC) market, backed by strong Q3 2025 performance and an expanding product portfolio. Despite challenges like competition and forex volatility, the company's attractive valuation and strategic collaborations position it for future success. Zacks analysts suggest adding this stock to portfolios due to its potential for business improvements.
Inogen (NASDAQ:INGN) Shares Cross Below Fifty Day Moving Average - Time to Sell?
Inogen (NASDAQ:INGN) shares recently crossed below their fifty-day moving average, trading at $6.71 with a 50-day moving average of $7.24. Analysts have a "Hold" consensus rating with a $11.00 price target, despite a recent "sell" reissuance from Weiss Ratings. The medical technology company, specializing in oxygen therapy solutions, reported mixed financial results, including negative net margin and return on equity, though quarterly EPS slightly topped estimates.
Inogen (NASDAQ:INGN) shareholders have endured a 85% loss from investing in the stock five years ago
Inogen (NASDAQ:INGN) shareholders have experienced a significant 85% loss over the last five years, with a 21% decline in the last twelve months and a 23% drop in the past three months. The company, which is not currently profitable, has seen minimal revenue growth of 0.4% per year over the last half-decade, disappointing the market. Despite insider buying activity, future profitability remains a key concern for investors.
Inogen (NASDAQ:INGN) shareholders have endured a 85% loss from investing in the stock five years ago
Inogen, Inc. (NASDAQ:INGN) shareholders have experienced a significant 85% loss over the past five years, with an additional 21% decline in the last twelve months. The company's revenue growth has been minimal at 0.4% per year, and it remains unprofitable, leading to market disappointment. Despite some insider buying, future profitability is crucial for a potential share price stabilization, as analysts are now focusing on earnings forecasts.
Here's why you should add Inogen stock to your portfolio now
This article suggests that Inogen (INGN) is a good stock to add to a portfolio. No specific reasons are provided in the content for this recommendation.
664,000 Shares in Inogen, Inc $INGN Bought by Armistice Capital LLC
Armistice Capital LLC recently purchased 664,000 shares of Inogen, Inc. (NASDAQ: INGN) for approximately $4.67 million, establishing a new position representing 2.46% of the company. Despite high institutional ownership and some funds increasing their stakes, analysts have a consensus "Hold" rating with an $11.00 target price, while Weiss Ratings reiterated a "Sell" due to the company's unprofitability. Inogen reported a slight earnings beat but continues to face challenges, trading around $7.02 with a market cap of $190.58 million.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Inogen, Inc. (INGN) is identified as a strong buy due to significant growth prospects in the portable oxygen concentrator (POC) market, a robust product portfolio, and strong third-quarter 2025 performance. The company’s attractive valuation and strategic collaborations, despite challenges like forex volatility and seasonal softness, position it for continued business improvements. The article highlights new product launches and FDA clearance as key drivers for future revenue growth.
Inogen, Inc $INGN Shares Bought by Divisadero Street Capital Management LP
Divisadero Street Capital Management LP significantly increased its stake in Inogen, Inc. ($INGN) by 192.3% in Q2, acquiring 299,571 shares and now owning 455,389 shares valued at $3.2 million. Other institutional investors also adjusted their holdings, with institutional ownership now at 89.94%. Despite slightly beating EPS estimates, Inogen remains unprofitable with a negative net margin and ROE, trading near $6.94 with a "Hold" consensus rating and an $11.00 price target.
Inogen (INGN) Down 0.6% Since Last Earnings Report: Can It Rebound?
Inogen (INGN) shares have decreased by 0.6% since its last earnings report, underperforming the S&P 500. The company's Q3 2025 earnings showed a narrower adjusted loss per share than expected, with revenues up 4% year-over-year but slightly missing consensus estimates. Despite this, Inogen has a Zacks Rank #2 (Buy) and a strong Growth Score of A, with estimates trending upward.
Inogen (INGN) Down 0.6% Since Last Earnings Report: Can It Rebound?
Inogen (INGN) has seen its shares drop 0.6% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss per share and a 4% year-over-year revenue increase in Q3 2025, driven by international and domestic business-to-business demand. Investors are now questioning whether the stock can rebound before its next earnings release, with estimates trending upward and a Zacks Rank #2 (Buy).
Inogen Appoints New President/CEO
Inogen Inc. has appointed Kevin Smith as its new President and Chief Executive Officer and a member of the Board of Directors. Smith brings over 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses. The Board believes his expertise will help scale the business, drive operational efficiencies, and accelerate growth for Inogen, a global leader in portable oxygen therapy solutions.
Prudential Financial Inc. Acquires 47,267 Shares of Inogen, Inc $INGN
Prudential Financial Inc. has increased its stake in Inogen, Inc (NASDAQ:INGN) by 7.9%, purchasing an additional 47,267 shares to bring its total holdings to 647,188 shares, valued at approximately $4.55 million. The company's stock, currently trading at $7.08, faces mixed analyst sentiment, with a consensus "Hold" rating and a target price of $11.00, despite recently beating EPS expectations but reporting negative net margin and return on equity. Institutional investors now own 89.94% of Inogen's stock.
Inogen, Inc. (NASDAQ:INGN) is largely controlled by institutional shareholders who own 73% of the company
Institutional shareholders hold a substantial 73% stake in Inogen, Inc. (NASDAQ:INGN), indicating significant influence over the company's share price. The top 14 shareholders collectively control 51% of the business, with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. being the largest shareholder at 9.7%. This institutional dominance suggests that major entities have assessed the stock favorably, but also highlights the potential risks associated with a "crowded trade" if multiple parties decide to sell simultaneously.
Inogen Inc expected to post a loss of 22 cents a share - Earnings Preview
Inogen Inc (INGN) is projected to report a loss of 22 cents per share for the quarter ending September 30, 2025, with an expected revenue increase of 3.8% to $92.2 million. Two analysts contributed to these estimates, based on LSEG data, with a "buy" rating as the current average for the shares. The company's stock has a median 12-month price target of $13.00, suggesting a potential upside of approximately 36.6% from its last closing price.
Inogen Announces Third Quarter 2025 Financial Results
Inogen, Inc. announced its financial results for the third quarter ended September 30, 2025, reporting $92.4 million in revenue, a 4.0% year-over-year increase, marking its seventh consecutive quarter of mid-single-digit growth. The company posted a GAAP net loss of $5.3 million but a positive adjusted EBITDA of $2.3 million. Inogen reiterated its full-year 2025 revenue guidance of $354 million to $357 million and raised its adjusted EBITDA guidance to approximately $2 million.
Inogen Inc (INGN) Q3 2025 Earnings Call Highlights: Sustained Revenue Growth Amid Strategic Shifts
Inogen Inc. reported its seventh consecutive quarter of mid-single-digit revenue growth in Q3 2025, reaching over $92 million, with a strong performance in the international B2B channel. The company also achieved adjusted EBITDA profitability for the third consecutive quarter and launched a new stationary oxygen concentrator, the Voxy 5. Despite these positives, direct-to-consumer sales declined, and the company reported a GAAP net loss due to one-time expenses, while it strategically shifts towards a leaner operating model and broadens its product portfolio.
Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y
Inogen (INGN) reported an adjusted loss per share of 2 cents for Q3 2025, beating the Zacks Consensus Estimate, and revenues of $92.4 million, up 4% year over year but slightly missing estimates. Despite the earnings beat, the stock dipped as domestic direct-to-consumer sales and rental revenues declined, and the company still incurred operating losses. However, the company is seeing strong demand from international and domestic business-to-business customers and launched new respiratory care products.
Inogen Announces Third Quarter 2025 Financial Results
Inogen (Nasdaq: INGN) announced its third-quarter 2025 financial results, reporting $92.4 million in revenue, a 4.0% year-over-year increase, marking its seventh consecutive quarter of mid-single-digit growth. The company achieved a GAAP net loss of $5.3 million and an adjusted net loss of $0.5 million, with an adjusted EBITDA of $2.3 million. Inogen reiterated its full-year 2025 revenue guidance of $354 million to $357 million and raised its adjusted EBITDA guidance to approximately $2 million.
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Inogen, Inc. (Nasdaq: INGN) announced it will report its second-quarter 2025 financial results after the market closes on Thursday, August 7, 2025. The company will host a conference call on the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested parties can access the call via dialing information provided or through a live audio webcast on Inogen's Investor Relations website.
Reviewing Inogen (NASDAQ:INGN) & Pressure BioSciences (OTCMKTS:PBIO)
This article provides a comparative review of Inogen (NASDAQ:INGN) and Pressure BioSciences (OTCMKTS:PBIO), examining their valuation, profitability, volatility, insider ownership, and analyst ratings. It highlights that while Pressure BioSciences has lower revenue, Inogen shows a stronger consensus rating and higher potential upside according to analysts. Detailed company profiles are also included.
Inogen to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Joplin Globe
Inogen, Inc. announced it will release its third quarter 2025 financial results on Wednesday, November 5, 2025, after the market closes. The company will host a conference call to discuss these results on the same day. Interested parties can access the live webcast and an archived recording on Inogen's investor relations website.
